Meeting
2021 Genitourinary Cancers Symposium
Transcriptome analysis of low-risk and high-risk non-muscular invasive bladder cancer patients to reveal disease progression related genes.
Authors
Zhichao Fu
GloriousMed Clinical Laboratory (Shanghai) Co., Ltd., Shanghai, China
Zhichao Fu , Shenghua Liu , Jianfei Wang , Yiqun Zhang , Yadong Yang , Tianyuan Xu , Shrestha Anil , Yang Yan , Cheng Li , Zongtai Zheng , Xin Li , Xudong Yao
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session: Urothelial Carcinoma
Track
Urothelial Carcinoma
Sub Track
Tumor Biology, Biomarkers, and Pathology
Citation
J Clin Oncol 39, 2021 (suppl 6; abstr 483)
DOI
10.1200/JCO.2021.39.6_suppl.483
Abstract #
483
Poster Bd #
Online Only
Abstract Disclosures
Similar Posters
Poster
2024 ASCO Genitourinary Cancers Symposium
Phase 3 KEYNOTE-676 cohort A: Bacillus Calmette-Guérin (BCG) with or without pembrolizumab for high-risk (HR) non–muscle-invasive bladder cancer (NMIBC) that persists/recurs after BCG induction.
First Author: Neal D. Shore
Poster
2022 ASCO Genitourinary Cancers Symposium
Characterizing molecular subtypes of high-risk nonmuscle-invasive bladder cancer in African American patients.
First Author: Stephen B. Williams
Poster
2018 Genitourinary Cancers Symposium
Vascular and tumor cell expression of VEGFR2 and molecular subtyping: An innovative biomarker approach in bladder cancer.
First Author: Aejaz Nasir
Poster
2024 ASCO Genitourinary Cancers Symposium
Punch: Preliminary results from a phase II study of intra‑arterial chemotherapy (IAC) combined with tislelizumab and bacillus Calmette-Guerin (BCG) in high-risk non-muscle-invasive bladder cancer (HR NMIBC).
First Author: Zongren Wang